Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Tempest Therapeutics Inc (TPST)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: TPST (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -90.84% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 32.50M USD | Price to earnings Ratio - | 1Y Target Price 9.5 |
Price to earnings Ratio - | 1Y Target Price 9.5 | ||
Volume (30-day avg) 533974 | Beta -2.57 | 52 Weeks Range 0.70 - 5.31 | Updated Date 04/2/2025 |
52 Weeks Range 0.70 - 5.31 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.5 |
Earnings Date
Report Date 2025-03-17 | When Before Market | Estimate -0.245 | Actual -0.31 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -77.01% | Return on Equity (TTM) -691.89% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 17599426 | Price to Sales(TTM) - |
Enterprise Value 17599426 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.31 | Shares Outstanding 45483400 | Shares Floating 40048147 |
Shares Outstanding 45483400 | Shares Floating 40048147 | ||
Percent Insiders 0.17 | Percent Institutions 15.54 |
Analyst Ratings
Rating 4.4 | Target Price 18.75 | Buy 3 | Strong Buy 2 |
Buy 3 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Tempest Therapeutics Inc
Company Overview
History and Background
Tempest Therapeutics, Inc. was founded in 2013 and is a clinical-stage biotechnology company focused on developing novel therapies that combine both innate and adaptive immunity to treat cancer. They are developing small molecule therapeutics that target pathways involved in the development of cancer.
Core Business Areas
- Oncology Drug Development: Focuses on discovering and developing small molecule therapeutics for cancer treatment.
Leadership and Structure
Dr. Stephen Brady is the CEO. The company has a typical biotech structure with departments for research and development, clinical operations, and business development. Leadership consists of executive team members.
Top Products and Market Share
Key Offerings
- TPST-1120: An oral selective PPARu03b1 antagonist, in clinical development for advanced solid tumors, specifically HCC (Hepatocellular Carcinoma). TPST-1120 is currently undergoing clinical trials, including a Phase 1b/2 trial. Competitors in the HCC space include Bristol-Myers Squibb (Opdivo), Roche (Tecentriq), and various other immunotherapy and targeted therapy approaches. Revenue and Market share data are currently not available.
Market Dynamics
Industry Overview
The oncology drug market is a large and rapidly growing market, driven by an increasing incidence of cancer and advancements in treatment options.
Positioning
Tempest Therapeutics is a clinical-stage company aiming to develop innovative cancer therapies. They focus on modulating the immune system within the tumor microenvironment.
Total Addressable Market (TAM)
The global oncology market is projected to reach hundreds of billions of dollars. Tempest is positioned to capture a portion of this market with its innovative therapies, targeting specific tumor types and mechanisms. The TAM for PPARu03b1 antagonists in oncology is currently undefined, but could be significant if clinical trials are successful.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach targeting tumor microenvironment
- Experienced management team
- Clinical-stage pipeline with a lead asset
- Focus on immuno-oncology which is a hot space
Weaknesses
- High cash burn rate typical of biotech companies
- Reliance on successful clinical trial outcomes
- Limited commercial infrastructure
- Dependence on partnerships or further funding.
Opportunities
- Successful clinical trial results leading to regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline with new drug candidates
- Potential for breakthrough therapy designation
Threats
- Clinical trial failures
- Competition from established players in oncology
- Regulatory hurdles
- Changes in the healthcare landscape
Competitors and Market Share
Key Competitors
- MRK
- BMY
- REGN
Competitive Landscape
Tempest faces intense competition from established pharmaceutical companies with significantly greater resources and marketing capabilities. The company's success hinges on demonstrating superior efficacy and safety with its novel therapies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: The company has not had significant revenue to date due to its stage.
Future Projections: Future growth depends on the success of TPST-1120 and other pipeline programs. Analyst estimates are highly variable and dependent on clinical trial results.
Recent Initiatives: Advancing TPST-1120 in clinical trials, exploring potential partnerships, and continuing research and development efforts.
Summary
Tempest Therapeutics is a clinical-stage biotech company with a promising lead candidate targeting the tumor microenvironment. The company's success depends on favorable clinical trial outcomes, securing partnerships, and managing its cash flow. As with all development stage companies, TPST is a high risk but potentially high reward stock. Financials show substantial losses and heavy dependence on future funding or strategic options.
Similar Companies
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
MRK
Merck & Company Inc
MRK
Merck & Company Inc
REGN
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- Company SEC Filings, Analyst Reports, Company Website
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made based on your own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tempest Therapeutics Inc
Exchange NASDAQ | Headquaters Brisbane, CA, United States | ||
IPO Launch date 2012-11-12 | CEO, President & Director Mr. Stephen R. Brady J.D., LLM | ||
Sector Healthcare | Industry Biotechnology | Full time employees 17 | Website https://www.tempesttx.com |
Full time employees 17 | Website https://www.tempesttx.com | ||
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. The company has agreement with Roche to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq®) and bevacizumab. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.